P. vivax radical cure in Latin America: regional coordination to advance malaria elimination 17 Dec 2021
First real-world use of new protocol for P. vivax case management in Brazil – a Health Ministry and MMV collaboration 08 Oct 2021
New Partnership launched to accelerate elimination of relapsing P. vivax malaria that poses a risk to an estimated 2.5 billion people worldwide 14 Jul 2021
STANDARD G6PD Test receives regulatory approval by the Australian Therapeutic Goods Administration 25 May 2021
GSK, MMV filing for Kozenis (tafenoquine) in paediatric populations with Plasmodium vivax malaria accepted by Australian Therapeutic Goods Administration 08 Jan 2021
GSK and MMV present positive data on treatment for Plasmodium vivax malaria in children from 6 months up to 15 years of age 19 Nov 2020
Event Highlights from the VivAccess Hosted Symposium at Virtual ASTMH: Accelerating New Tools for Radical Cure of Vivax Malaria from Clinical and Operational Research to Policy 18 Nov 2020